Loading data for SLDB — first visit, this takes a few seconds.

Alerta

Solid Biosciences Inc. (SLDB)

NasdaqGS: SLDB · Precio en tiempo real · USD

9.70

+0.62 (6.83%)

Al cierre: Aug 18, 2026, 3:59 PM

6.83% (1D)

Precio de compra	7.03
Capitalización de mercado	1.03B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-207.1M
Beta	2.42
EPS (TTM)	-1.89
Ratio PER (TTM)	n/a
Adelante PE	-5.48
P/B (TTM)	2.69
P/S (TTM)	n/a
Earnings Date	Nov 2, 2026

Precio de venta	12.01
Volumen	264,557
Volumen medio (20D)	1,613,285
Abierto	9.42
Anterior Cerrar	9.08
Rango del día	9.29 - 9.87
Rango de 52 semanas	3.79 - 11.45
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de SLDB

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jan 26, 2018

Empleados 121

Bolsa de Valores NasdaqGS

Símbolo bursátil SLDB

Sitio web https://www.solidbio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Solid Biosciences fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -174.32M, un aumento de 39.8%.

Estados financieros

Sorpresa de resultados

Solid Biosciences ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.38 supera las estimaciones en 0.09, con 35.59% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Solid Biosciences Inc. publique sus resultados el Nov 2, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 mes hace · Simply Wall St.

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

In late June 2026, Solid Biosciences Inc. was added to several Russell growth indexes, including the Russell 3000 Growth, 2000 Growth, 2500 Growth, and Microcap Growth benchmarks. This broad index inc...

2 meses hace · MT Newswires

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,

3 meses hace · Insider Monkey

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged mor...

5 meses hace · TipRanks

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomark...

5 meses hace · Motley Fool

Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks

Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.

Página 1 de 2

Solid Biosciences Inc. (SLDB)